Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Fostamatinib disodium by Rigel Pharmaceuticals for Hidradenitis Suppurativa: Likelihood of Approval
Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData,...